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 Understanding the dynamics of Plasmodium falciparum parasite population in terms  of drug 
resistance is of paramount importance especially in Myanmar, a country with increasing prevalence of 
artemisinin resistance and the greatest burden of malaria in the Greater Mekhong Sub-region. Here, I 
attempt to clarify how change of drug treatment policy in Myanmar, particularly dramatic increase in 
artemisinin usage, affected population dynamics of P. falciparum.  
  Blood samples from patients infected with P. falciparum were collected from four areas in two 
periods; before (2002-5) and after (2013), the official implementation of artemisinin combination therapies 
(ACTs) in Myanmar. I determined variants of newly identified artemisinin-resistant gene (kelch 13) and 
well-known chloroquine and pyrimethamine/sulfadoxine resistant genes (pfcrt, pfmdr1, dhfr, and dhps). To 
clarify the evolutionary lineages of anti-malarial resistant parasites, microsatellite markers flanking pfcrt, 
dhfr and dhps were assessed and compared to those in the other endemic regions.  
 In artemisinin resistance, a significant increase in the prevalence of parasites harboring kelch 13 
mutation was observed from 8.6% in 2002-2005 to 24% in 2013 (p = 0.0031). One novel mutation (Y511H) 
was observed in the 14.8% of samples in 2013, suggesting potential selection after the ACTs initiation. In 
contrast, three SNPs (G449A, R561H and C580Y) that have been reported to be associated with artemisinin 
resistance in the Greater Mekhong Sub-region were not identified. Almost all fixation of pfcrt K76T and 
overwhelming of highly resistant types of dhfr and dhps mutant parasites persisted even after the 
withdrawal of official chloroquine and pyrimethamine/sulfadoxine usage. Lineages of chloroquine and 
pyrimethamine/sulfadoxine resistant parasites were shared between Myanmar and other endemic countries 
in Asia and Africa.  
 This study suggests that artemisinin resistance arose independently and was selected  in 
Myanmar, in sharp contrast to chloroquine and pyrimethamine/sulfadoxine resistance. Change of malaria 
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treatment regime has not induced any sign of reduction of chloroquine and SP resistant P. falciparum. These 
molecular epidemiological observations regarding the dynamics of molecular markers for anti-malarial 
resistance after the introduction of ACTs in Myanmar will provide an insight into future policy making for 
implementing a strategy to prevent and control artemisinin resistance, initially in the Mekong subregion, 
expanding worldwide and utilising multi-drug regimens with different ACTs.  
 
 
 
 
